Q2 FY2026 · ended Jun 30, 2026 · Revenue $0 · Filed Aug 6, 2026
Evommune, Inc. (EVMN) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $32.2 million. Free cash flow was -$20.5 million. As of Jun 30, 2026 it held $288.0 million in cash and investments and $8.6 million in total debt.
Revenue
$0
Net income
$-32.25M
-48.8% vs prior quarter
Operating cash flow
$-20.32M
+26.1% vs prior quarter
Free cash flow
$-20.50M
+25.7% vs prior quarter
EPS
$-0.89
-39.1% vs prior quarter
Dividend per share
None
Shares outstanding
36.29M
+0.8% vs prior quarter
Net cash
$279.38M
Q2 FY2026
Operating margin
-133.3%
Q3 FY2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- EVMN (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Palo Alto, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2044725
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $10.0M |
| Operating income | -$34.9M | -$24.0M | -$29.7M | -$13.3M |
| Net income | -$32.2M | -$21.7M | -$28.3M | -$12.5M |
| Diluted EPS | -$0.89 | -$0.64 | -$1.43 | -$8.07 |
| Operating cash flow | -$20.3M | -$27.5M | -$16.7M | -$59.7M |
| Free cash flow | -$20.5M | -$27.6M | -$16.8M | -$59.9M |
| Total assets | $301.9M | $322.5M | $224.9M | $84.5M |
| Total liabilities | $24.4M | $17.9M | $19.4M | $10.7M |
| Stockholders' equity | $277.6M | $304.6M | $205.6M | -$183.1M |
| Cash and investments | $288.0M | $307.0M | $216.7M | $76.1M |
| Total debt | $8.6M | $9.1M | $2.1M | $765,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure, Other events
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 1, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 23, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 15, 2026 | Sep 15, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 9, 2026 | Sep 8, 2026 |
All 138 Evommune, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.